Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 5 (May)

1. Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules.
   J Nucl Med, 49(5): 804-13. [Abstract] [Full-text]
2. Targeted Therapies for the Treatment of Breast Cancer in the Post-trastuzumab Era.
   Oncologist, 13(4): 373-81. [Abstract] [Full-text]
3. Trastuzumab plus Paclitaxel or Docetaxel in HER-2-Negative/HER-2 ECD-Positive Anthracycline- and Taxane-Refractory Advanced Breast Cancer.
   Oncologist, 13(4): 361-9. [Abstract] [Full-text]
4. Synergistic Growth Inhibition by 9-cis-Retinoic Acid Plus Trastuzumab in Human Hepatocellular Carcinoma Cells.
   Clin Cancer Res, 14(9): 2806-12. [Abstract] [Full-text]
5. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer.
   Clin Cancer Res, 14(9): 2710-6. [Abstract] [Full-text]
6. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
   Breast. [Abstract] [Full-text]
7. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.
   Br J Cancer, 98(9): 1525-32. [Abstract] [Full-text]
8. Chemotherapy for metastatic gastric cancer: past, present, and future.
   J Gastroenterol, 43(4): 256-64. [Abstract] [Full-text]
9. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
   Breast Cancer Res Treat, 109(2): 231-9. [Abstract] [Full-text]
10. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
    Ann Surg Oncol, 15(6): 1677-88. [Abstract] [Full-text]
11. Treatment-experienced breast cancer.
    Am J Health Syst Pharm, 65(10): S4-9. [Abstract] [Full-text]
12. Treatment of metastatic breast cancer: looking towards the future.
    Breast Cancer Res Treat. [Abstract] [Full-text]
13. Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study.
    BMC Health Serv Res, 8: 70. [Abstract] [Full-text]
14. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    J Clin Oncol, 26(14): 2373-8. [Abstract] [Full-text]
15. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
    J Mol Cell Cardiol, 44(5): 831-54. [Abstract] [Full-text]
16. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Oncogene. [Abstract] [Full-text]
17. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
    Breast Cancer Res Treat, 109(3): 559-66. [Abstract] [Full-text]
18. Differences in radiosensitivity between three HER2 overexpressing cell lines.
    Eur J Nucl Med Mol Imaging, 35(6): 1179-91. [Abstract] [Full-text]
19. The role of Herceptin in early breast cancer.
    Int Semin Surg Oncol, 5: 9. [Abstract] [Full-text]
20. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
    Breast Cancer. [Abstract] [Full-text]
21. Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys.
    Gene Ther. [Abstract] [Full-text]
22. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
    Ann Oncol. [Abstract] [Full-text]
23. Prolonged trastuzumab therapy in a patient with recurrent breast cancer and anthracycline-induced cardiac failure.
    Breast. [Abstract] [Full-text]
24. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy.
    Am J Clin Pathol, 129(6): 907-11. [Abstract] [Full-text]
25. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer : A Hellenic Cooperative Oncology Group study.
    Breast Cancer Res Treat. [Abstract] [Full-text]
26. Factors influencing the time to development of brain metastases in breast cancer.
    Breast. [Abstract] [Full-text]
27. Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer.
    J Clin Oncol. [Abstract] [Full-text]
28. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
    Histopathology, 52(7): 797-805. [Abstract] [Full-text]
29. Cardiotoxicity of antitumor drugs.
    Chem Res Toxicol, 21(5): 978-89. [Abstract] [Full-text]
30. Immunohistochemical antibodies in breast cancer HER2 diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study.
    Tumour Biol, 29(1): 18-27. [Abstract] [Full-text]
31. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
    Cancer, 112(11): 2359-67. [Abstract] [Full-text]
32. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review.
    Cancer Treat Rev. [Abstract] [Full-text]
33. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer.
    Cancer Treat Rev, 34(4): 378-90. [Abstract] [Full-text]
34. Molecular testing for somatic mutations in common cancers: the views of UK oncologists.
    J Clin Pathol, 61(6): 761-5. [Abstract] [Full-text]
35. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
    Ann Oncol, 19(6): 1090-6. [Abstract] [Full-text]
36. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Ann Oncol, 19(6): 1097-109. [Abstract] [Full-text]
37. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
    Ann Oncol, 19(6): 1068-74. [Abstract] [Full-text]
38. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study.
    Ann Oncol, 19(6): 1110-6. [Abstract] [Full-text]
39. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Nat Clin Pract Oncol, 5(6): 324-35. [Abstract] [Full-text]
40. Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: A computational approach.
    C R Biol, 331(6): 409-17. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.